Latest Licensing News

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Evergreen Lithium has secured rights to two promising gold projects in Western Australia’s premier goldfields, significantly boosting its exploration footprint with minimal upfront cash outlay. The acquisitions position the company to leverage historical data and regional infrastructure as it advances toward becoming a gold producer.

Estrella Resources and its partner PT Raka Energi Mandiri have agreed to extend key project milestones for their Werumata limestone venture in Timor-Leste, reflecting internal delays but maintaining a positive outlook.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Centrepoint Alliance has reported a robust FY25 financial performance, surpassing earnings guidance with a 16% rise in EBITDA and a 30% jump in pre-tax profits. The company also declared a 1.75 cent final dividend and advanced its technology and advisory services.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Asset Vision reported robust FY25 results with significant revenue and cash flow growth, achieving a debt-free status while advancing its AI-powered asset management platform.

Asset Vision Co Limited reported a 22.9% increase in revenue to $5.03 million for FY2025, alongside a widening net loss of $385,797. The company’s Annual Recurring Revenue surged 28%, supported by new contracts and product innovation.

Meteoric Resources confirms its Caldeira Rare Earth Project in Brazil remains on track after a disputed environmental council vote was declared invalid. Strong local government support and regulatory assurances underpin confidence in project timelines.